Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

2015, European journal of cancer (Oxford, England : 1990), 51, S625

2011, Clinical Cancer Research, 17, 1169, 10.1158/1078-0432.CCR-10-2277

2014, Cancer Discovery, 4, 1046, 10.1158/2159-8290.CD-14-0337

2014, Journal of medicinal chemistry, 57, 8249, 10.1021/jm500973a

Hamilton, 1981, Clinical pharmacology and therapeutics, 29, 408, 10.1038/clpt.1981.56

2015, New England Journal of Medicine, 372, 1689, 10.1056/NEJMoa1411817

2011, Journal of Clinical Oncology, 29, 2121, 10.1200/JCO.2010.31.8923

Kobayashi, 2005, New England Journal of Medicine, 352, 786, 10.1056/NEJMoa044238

2014, Lung cancer (Amsterdam, Netherlands), 85, 19, 10.1016/j.lungcan.2014.03.016

2016, Journal of Clinical Oncology, 34, Abstract9002, 10.1200/JCO.2016.34.15_suppl.9002

2014, Lung cancer (Amsterdam, Netherlands), 84, 295, 10.1016/j.lungcan.2014.03.011

2011, Clinical Cancer Research, 17, 1616, 10.1158/1078-0432.CCR-10-2692

Pao, 2005, 2, e73, 10.1371/journal.pmed.0020073

2005, Annual review of pharmacology and toxicology, 45, 177, 10.1146/annurev.pharmtox.45.120403.100058

2016, Cancer chemotherapy and pharmacology, 77, 767, 10.1007/s00280-016-2992-z

2014, Annals of Oncology, 25, iii27, 10.1093/annonc/mdu199

Sequist, 2011, Science Translational Medicine, 3, 75ra26, 10.1126/scitranslmed.3002003

2015, Drug Metabolism and Disposition, 43, 375, 10.1124/dmd.114.061424

Stopfer, 2012, Cancer chemotherapy and pharmacology, 69, 1051, 10.1007/s00280-011-1803-9

2011, 2011, 960

2013, Clinical Cancer Research, 19, 2240, 10.1158/1078-0432.CCR-12-2246

Zhou, 2005, Drug metabolism reviews, 37, 41, 10.1081/DMR-28812